Updates on menin inhibitors for acute leukemia and the pushback of revumenib approval

Eunice Wang, MD, Roswell Park Cancer Center, Buffalo, NY, discusses the four menin inhibitors currently in clinical development for the treatment of relapsed/refractory (R/R) KMT2A-rearranged and NMP1-mutated acute leukemias. Although she recognizes that menin inhibitors may not be effective for other subtypes of acute leukemia, she believes that these agents will be the next approved treatments for these subsets. She also discusses the PDUFA pushback of revumenib. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.